SG10201607331WA - Cardiovascular risk event prediction and uses thereof - Google Patents

Cardiovascular risk event prediction and uses thereof

Info

Publication number
SG10201607331WA
SG10201607331WA SG10201607331WA SG10201607331WA SG10201607331WA SG 10201607331W A SG10201607331W A SG 10201607331WA SG 10201607331W A SG10201607331W A SG 10201607331WA SG 10201607331W A SG10201607331W A SG 10201607331WA SG 10201607331W A SG10201607331W A SG 10201607331WA
Authority
SG
Singapore
Prior art keywords
cardiovascular risk
risk event
event prediction
prediction
cardiovascular
Prior art date
Application number
SG10201607331WA
Other languages
English (en)
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of SG10201607331WA publication Critical patent/SG10201607331WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG10201607331WA 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof SG10201607331WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30

Publications (1)

Publication Number Publication Date
SG10201607331WA true SG10201607331WA (en) 2016-11-29

Family

ID=47993164

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201607331WA SG10201607331WA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof
SG10201906900QA SG10201906900QA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof
SG11201400904SA SG11201400904SA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201906900QA SG10201906900QA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof
SG11201400904SA SG11201400904SA (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Country Status (16)

Country Link
US (3) US20130085079A1 (enrdf_load_stackoverflow)
EP (1) EP2761289B1 (enrdf_load_stackoverflow)
JP (3) JP6652781B2 (enrdf_load_stackoverflow)
KR (2) KR102248900B1 (enrdf_load_stackoverflow)
CN (4) CN107422126B (enrdf_load_stackoverflow)
AU (1) AU2013202112B9 (enrdf_load_stackoverflow)
BR (2) BR122019023720B1 (enrdf_load_stackoverflow)
CA (2) CA2847903C (enrdf_load_stackoverflow)
ES (1) ES2777002T3 (enrdf_load_stackoverflow)
IL (1) IL231387A (enrdf_load_stackoverflow)
IN (1) IN2014CN01970A (enrdf_load_stackoverflow)
MX (2) MX373248B (enrdf_load_stackoverflow)
RU (1) RU2651708C2 (enrdf_load_stackoverflow)
SG (3) SG10201607331WA (enrdf_load_stackoverflow)
WO (1) WO2013049674A1 (enrdf_load_stackoverflow)
ZA (1) ZA201401778B (enrdf_load_stackoverflow)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2011154689A1 (en) * 2010-06-07 2011-12-15 King's College London Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection
BR112012032537B8 (pt) 2010-07-09 2022-10-18 Somalogic Inc Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
JP6018096B2 (ja) 2011-03-10 2016-11-02 ソマロジック・インコーポレーテッド クロストリジウム・ディフィシレ診断法のためのアプタマー
CN107422126B (zh) * 2011-09-30 2020-03-27 私募蛋白质体公司 心血管危险事件预测及其用途
CN108359711A (zh) 2012-01-27 2018-08-03 利兰斯坦福青年大学董事会 解析和定量无细胞rna的方法
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
WO2015048084A1 (en) 2013-09-24 2015-04-02 Somalogic, Inc. Multiaptamer target detection
EP3120148B1 (en) * 2014-03-21 2019-01-30 Sanofi-Aventis Deutschland GmbH New markers for the assessment of the risk for development of a cardiovascular disorder
CA2949731A1 (en) * 2014-06-05 2015-12-10 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
AU2014407088B2 (en) * 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CA2992139A1 (en) * 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
EP4513191A3 (en) * 2016-02-08 2025-06-04 SomaLogic Operating Co., Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
US20190071795A1 (en) * 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
WO2017174696A1 (en) * 2016-04-06 2017-10-12 Nestec S.A. Biomarkers for predicting degree of weight loss
JP6679051B2 (ja) 2016-04-15 2020-04-15 オムロン株式会社 生体情報分析装置、システム、及び、プログラム
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
CN111480081A (zh) * 2017-12-13 2020-07-31 豪夫迈·罗氏有限公司 用于预测脑卒中的循环血管生成素-2(Ang-2)和胰岛素样生长因子结合蛋白7(IGFBP7)
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
KR20210044216A (ko) * 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
US20210327540A1 (en) * 2018-08-17 2021-10-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
CN113302498B (zh) * 2018-08-22 2024-07-30 豪夫迈·罗氏有限公司 循环spon-1（脊椎蛋白-1）在心房颤动评定中的应用
EP3874275B1 (en) * 2018-10-31 2022-11-23 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Biomarkers of subclinical atherosclerosis
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
CN113692624A (zh) 2019-02-14 2021-11-23 米尔维公司 用于确定受试者的妊娠相关状态的方法和系统
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
JP7712913B2 (ja) * 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP7510649B2 (ja) * 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
TW202201007A (zh) * 2020-05-19 2022-01-01 美商獵鷹生科有限責任公司 以灌注不足為特徵的病症的檢測和治療
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy A method of determining whether a subject has a disease or condition or is at risk of developing a disease or condition
US20230393146A1 (en) * 2020-10-20 2023-12-07 Somalogic Operating Co., Inc. Cardiovascular Event Risk Prediction
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
US20240060998A1 (en) * 2021-02-01 2024-02-22 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
US20250248660A1 (en) * 2021-08-26 2025-08-07 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
WO2024226519A2 (en) * 2023-04-24 2024-10-31 Google Llc Deep learning-based photoplethysmography model for cardiovascular risk prediction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20030144476A1 (en) * 2000-03-06 2003-07-31 Pankaj Agarwal Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1532269B1 (en) * 2002-05-09 2011-11-23 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
EP1825265A4 (en) * 2004-12-10 2008-08-27 Univ Maryland AMYLOID SERUM PROTEIN USED AGAINST INFLAMMATION AND OBESITY
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
CN101374956B (zh) * 2006-01-31 2014-01-01 三菱化学美迪恩斯株式会社 弥漫性血管内凝血综合征的病态鉴定方法
WO2007103568A2 (en) * 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
HRP20130287T1 (en) * 2007-08-02 2013-05-31 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
JP2012500199A (ja) * 2008-08-11 2012-01-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 血管統合性を促進するマイクロ−ｒｎａおよびその使用
CN107085114B (zh) * 2008-10-07 2021-05-25 B.R.A.H.M.S有限公司 用于预测初次不利事件的生物标志物
JP5678045B2 (ja) * 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
EA201270020A1 (ru) * 2009-06-15 2012-07-30 Кардиодкс, Инк. Определение риска развития атеросклеротической болезни сердца
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
EP2510116A2 (en) * 2009-12-09 2012-10-17 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
US20120322862A1 (en) * 2010-03-03 2012-12-20 Somalogic, Inc. Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders
CN107422126B (zh) * 2011-09-30 2020-03-27 私募蛋白质体公司 心血管危险事件预测及其用途
CA2901394A1 (en) * 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure

Also Published As

Publication number Publication date
CN107422126A (zh) 2017-12-01
ZA201401778B (en) 2018-08-25
BR122019023720A2 (enrdf_load_stackoverflow) 2017-04-04
CN103959060B (zh) 2017-05-17
IL231387A (en) 2017-12-31
EP2761289A4 (en) 2015-08-12
IL231387A0 (en) 2014-04-30
KR102248900B1 (ko) 2021-05-07
RU2651708C2 (ru) 2018-04-23
CN107102151A (zh) 2017-08-29
US20200166523A1 (en) 2020-05-28
CN103959060A (zh) 2014-07-30
BR112014007214B1 (pt) 2022-08-16
CA3074279A1 (en) 2013-04-04
CA3074279C (en) 2021-10-19
AU2013202112B9 (en) 2015-10-22
EP2761289B1 (en) 2020-02-12
HK1247666A1 (zh) 2018-09-28
JP6546318B2 (ja) 2019-07-17
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
EP2761289A1 (en) 2014-08-06
SG11201400904SA (en) 2014-04-28
BR112014007214A2 (pt) 2017-04-04
US20150168423A1 (en) 2015-06-18
JP6652781B2 (ja) 2020-02-26
CA2847903C (en) 2020-10-27
JP2020024216A (ja) 2020-02-13
MX2014003153A (es) 2014-04-30
JP6917432B2 (ja) 2021-08-11
MX373248B (es) 2020-05-11
AU2013202112B2 (en) 2015-09-24
WO2013049674A1 (en) 2013-04-04
BR122019023720A8 (pt) 2022-07-26
KR20140084106A (ko) 2014-07-04
JP2018159713A (ja) 2018-10-11
ES2777002T3 (es) 2020-08-03
IN2014CN01970A (enrdf_load_stackoverflow) 2015-05-29
CN114518458A (zh) 2022-05-20
NZ622118A (en) 2016-01-29
US20130085079A1 (en) 2013-04-04
RU2014110508A (ru) 2015-11-10
KR102111624B1 (ko) 2020-05-18
SG10201906900QA (en) 2019-09-27
MX2020004617A (es) 2020-08-06
BR112014007214A8 (pt) 2022-07-26
KR20200055804A (ko) 2020-05-21
AU2013202112A1 (en) 2013-05-02
BR122019023720B1 (pt) 2023-01-24
JP2014528576A (ja) 2014-10-27

Similar Documents

Publication Publication Date Title
ZA201401778B (en) Cardiovascular risk event prediction and uses thereof
IL233051B (en) Anti-phf-tau antibodies and uses thereof
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL229844B (en) Anti-psgl-1 antibodies and their use
EP2793894A4 (en) HETEROARYLE AND USES THEREOF
PL2822682T3 (pl) Mikrokapsułki i ich zastosowanie
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
PL2667710T3 (pl) Kompozycja owadobójcza i związane z nią sposoby
EP2716359A4 (en) COMPLEX AND USES THEREOF
HUE040567T2 (hu) Szkrínelõ eljárások és azok alkalmazásai
GB201111775D0 (en) Compounds and uses thereof
EP2712348A4 (en) DISTRIBUTOR AND METHODS
GB201108490D0 (en) Methods and uses
GB2504239B (en) Snap-hook
GB201117881D0 (en) Biomarkers and uses thereof
GB201119443D0 (en) GoWinging Concept and patent
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
GB201119123D0 (en) Interthermic and intrathermic spectroscopy
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
GB201117780D0 (en) Tool-lock karabiner
PL119176U1 (pl) Podręcznik
GB201105091D0 (en) Animated terms and conditions
TWM389317U (en) Personal effects alarm